Non Animal Testing Database
EnglischDeutsch

In silico identification of multi-target ligands for neurodegenerative diseases drug development

November 2022
Bulgarian Academy of Sciences, Sofia, Bulgaria
The conventional treatment of neurodegenerative diseases (NDDs) is based on the “one molecule—one target” paradigm. To combat the multifactorial nature of NDDs, the focus is now shifted toward the development of small-molecule-based compounds that can modulate more than one protein target, known as “multi-target-directed ligands” (MTDLs), while having low affinity for proteins that are irrelevant for the therapy. In this study, more than 650,000 compounds were screened by a series of in silico approaches to identify drug-like compounds with predicted activity simultaneously towards three important proteins in the NDDs symptomatic treatment. Four selected hits underwent subsequent refinement through in silico blood-brain barrier penetration estimation, safety evaluation, and molecular dynamics simulations, resulting in two hit compounds that constitute a rational basis for further development of multi-target active compounds against NDDs.
In silico identification of multi-target ligands as promising hit compounds for neurodegenerative diseases drug development
Nikolay T. Tzvetkov, Ivanka Tsakovska
#1642
Added on: 11-28-2022
Back to Top
English German

Warning: Internet Explorer

The IE from MS no longer understands current scripting languages, the latest main version (version 11) is from 2013 and has not been further developed since 2015.

Our recommendation: Use only the latest versions of modern browsers, for example Google Chrome, Mozilla Firefox or Microsofrt Edge, because only this guarantees you sufficient protection against infections and the correct display of websites!